WO2014166029A1 - 针对表皮生长因子受体的抗体 - Google Patents
针对表皮生长因子受体的抗体 Download PDFInfo
- Publication number
- WO2014166029A1 WO2014166029A1 PCT/CN2013/073811 CN2013073811W WO2014166029A1 WO 2014166029 A1 WO2014166029 A1 WO 2014166029A1 CN 2013073811 W CN2013073811 W CN 2013073811W WO 2014166029 A1 WO2014166029 A1 WO 2014166029A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- egfr
- heavy chain
- functional fragment
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13881974.3A EP2985292A4 (en) | 2013-04-07 | 2013-04-07 | ANTIBODY OF THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR |
BR112015025549A BR112015025549A2 (pt) | 2013-04-07 | 2013-04-07 | anticorpo contra o receptor do fator de crescimento epidérmico |
RU2015147913A RU2652880C2 (ru) | 2013-04-07 | 2013-04-07 | Антитело против рецептора эпидермального фактора роста |
PCT/CN2013/073811 WO2014166029A1 (zh) | 2013-04-07 | 2013-04-07 | 针对表皮生长因子受体的抗体 |
US14/876,053 US9644031B2 (en) | 2013-04-07 | 2015-10-06 | Epidermal growth factor receptor antibody |
ZA2015/08035A ZA201508035B (en) | 2013-04-07 | 2015-10-29 | Epidermal growth factor receptor antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/073811 WO2014166029A1 (zh) | 2013-04-07 | 2013-04-07 | 针对表皮生长因子受体的抗体 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/876,053 Continuation US9644031B2 (en) | 2013-04-07 | 2015-10-06 | Epidermal growth factor receptor antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014166029A1 true WO2014166029A1 (zh) | 2014-10-16 |
Family
ID=51688811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/073811 WO2014166029A1 (zh) | 2013-04-07 | 2013-04-07 | 针对表皮生长因子受体的抗体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9644031B2 (zh) |
EP (1) | EP2985292A4 (zh) |
BR (1) | BR112015025549A2 (zh) |
RU (1) | RU2652880C2 (zh) |
WO (1) | WO2014166029A1 (zh) |
ZA (1) | ZA201508035B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24613B1 (es) | 2016-02-06 | 2022-07-08 | Epimab Biotherapeutics Inc | Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr |
US20220017617A1 (en) * | 2018-07-09 | 2022-01-20 | Shanghai Epimab Biotherapeutics Co., Ltd. | Efficiently expressed egfr and pd-l1 bispecific binding proteins |
WO2020084608A1 (en) * | 2018-10-22 | 2020-04-30 | Explore Bio 1 Ltd | Precursor bispecific antibody constructs and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO2011028811A2 (en) * | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100497389C (zh) * | 2001-06-13 | 2009-06-10 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
ES2387809T3 (es) * | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
JP4686634B2 (ja) * | 2006-06-02 | 2011-05-25 | アベオ ファーマシューティカルズ, インコーポレイテッド | 肝細胞成長因子(hgf)結合蛋白質 |
SG190572A1 (en) * | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
RU2010153578A (ru) * | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
RU2011104348A (ru) * | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
JP6014596B2 (ja) * | 2010-11-09 | 2016-10-25 | メディミューン,エルエルシー | 均一コンジュゲーションのための抗体足場 |
CN103619881B (zh) * | 2011-04-07 | 2017-07-28 | 安姆根有限公司 | 新的egfr结合蛋白 |
CN103172741B (zh) * | 2011-12-20 | 2018-04-27 | 智翔(上海)医药科技有限公司 | 全人源抗egfr抗体 |
-
2013
- 2013-04-07 WO PCT/CN2013/073811 patent/WO2014166029A1/zh active Application Filing
- 2013-04-07 EP EP13881974.3A patent/EP2985292A4/en not_active Withdrawn
- 2013-04-07 BR BR112015025549A patent/BR112015025549A2/pt not_active Application Discontinuation
- 2013-04-07 RU RU2015147913A patent/RU2652880C2/ru not_active IP Right Cessation
-
2015
- 2015-10-06 US US14/876,053 patent/US9644031B2/en not_active Expired - Fee Related
- 2015-10-29 ZA ZA2015/08035A patent/ZA201508035B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO2011028811A2 (en) * | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
Non-Patent Citations (10)
Title |
---|
BLEEKER WK; LAMMERTS VAN BUEREN JJ; VAN OJIK HH; GERRITSEN AF; PLUYTER M; HOUTKAMP M; HALK E; GOLDSTEIN J; SCHUURMAN J; VAN DIJK M: "Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy", J IMMUNOL, vol. 173, 2004, pages 4699 - 707, XP002358777 |
CASTILLO L; ETIENNE-GRIMALDI MC; FISCHEL JL ET AL.: "Pharmacological background of EGFR targeting", ANN ONCOL, vol. 15, 2004, pages 1007 - 1012, XP002402776, DOI: doi:10.1093/annonc/mdh257 |
JORISSEN RN; WALKER F; POULIOT N ET AL.: "Epidermal growth factor receptor: mechanisms of activation and signaling", EXP CELL RES, vol. 284, 2003, pages 31 - 53 |
KABAT ET AL.: "SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST", 1991, NATIONAL INSTITUTES OF HEALTH |
MENDELSOHN J; BASELGA J: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer", J CLIN ONCOL, vol. 21, 2003, pages 2787 - 2799 |
OLAYIOYE MA; NEVE RM; LANE HA ET AL.: "The EerbB Signaling network: receptor heterodimerzat ion in development and cancer", THE EMBO J, vol. 19, 2000, pages 3159 - 3167 |
PATEL D; GUO X; NG S; MELCHIOR M; BALDERES P; BURTRUM D; PERSAUD K; LUNA X; LUDWIG DL; KANG X: "IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab", HUM ANTIBODIES, vol. 19, 2010, pages 89 - 99, XP009172959, DOI: doi:10.3233/HAB-2010-0232 |
SCHNEIDER-MERCK, T. ET AL.: "Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage", J IMMUNOL., vol. 184, no. 1, 1 January 2010 (2010-01-01), pages 512 - 520, XP055270382 * |
See also references of EP2985292A4 |
Z STEPLEWSKI; L K SUN; C W SHEARMAN; J GHRAYEB; P DADDONA; H KOPROWSKI: "Biological Activity of Human-Mouse IgGl, IgG2, IgG3, and IgG4 chimeric monoclonal Antibodies with antitumor specificity", PNAS, vol. 85, 1988, pages 4852 - 4856, XP001007415, DOI: doi:10.1073/pnas.85.13.4852 |
Also Published As
Publication number | Publication date |
---|---|
EP2985292A4 (en) | 2016-12-21 |
US9644031B2 (en) | 2017-05-09 |
BR112015025549A2 (pt) | 2017-10-10 |
RU2015147913A (ru) | 2017-05-15 |
RU2652880C2 (ru) | 2018-05-03 |
US20160017045A1 (en) | 2016-01-21 |
EP2985292A1 (en) | 2016-02-17 |
ZA201508035B (en) | 2018-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7374995B2 (ja) | 抗pd-1/抗vegfa二官能性抗体、その医薬組成物およびその使用 | |
JP2017506217A (ja) | 標的TGFβ阻害 | |
JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体(ron)の阻害 | |
US9822174B2 (en) | Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same | |
ES2699584T3 (es) | Anticuerpos multifuncionales que se unen a EGFR y MET | |
US10759859B2 (en) | Anti-PD-1 antibodies and uses thereof | |
AU2020353235A1 (en) | Cytokine prodrugs and dual-prodrugs | |
CN114269782B (zh) | 抗tigit抗体及其应用 | |
WO2019114793A1 (zh) | 一种egfr抗体及其制备方法和应用 | |
US9644031B2 (en) | Epidermal growth factor receptor antibody | |
CN103172741B (zh) | 全人源抗egfr抗体 | |
WO2020014098A1 (en) | Efficiently expressed egfr and pd-l1 bispecific binding proteins | |
TW202334228A (zh) | B7h6抗體及其應用 | |
AU2021403263B2 (en) | Bispecific antibody for specifically neutralizing tgf-β signal of helper t cell, and pharmaceutical combination and use thereof | |
WO2021244553A1 (zh) | 一种抗pd-l1和egfr的四价双特异性抗体 | |
CN112175087B (zh) | 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途 | |
CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
KR20130057959A (ko) | 항 her2 단일클론항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물 | |
WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
US20240052065A1 (en) | Binding molecules for the treatment of cancer | |
CN117510641A (zh) | 靶向cd112r和tigit的双特异性抗体及其用途 | |
KR101631646B1 (ko) | VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체 | |
EP4277922A2 (en) | Chimeric molecules comprising il-12 agonist polypeptide | |
CN112867737A (zh) | 抗cd137抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13881974 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013881974 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015147913 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015025549 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015025549 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151006 |